SPL-IN-1

• Description :

  SPL-IN-1 (compound C17) is a dual species sphingosine-1-phosphate lyase inhibitor[1].

• UNSPSC :

  12352005

• Target :

  LPL Receptor

• Type :

  Reference compound

• Related Pathways :

  GPCR/G Protein

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/spl-in-1.html

• Solubility :

  10 mM in DMSO

• Smiles :

  CCCOC(C1=C(SC2=C1CCCCC2)NC(CCCC(NC3=C(C4=C(S3)CCCCC4)C(OCCC)=O)=O)=O)=O

• Molecular Formula :

  C31H42N2O6S2

• Molecular Weight :

  602.80

• References & Citations :

  [1]Cellini B, et al. Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study. Sci Rep. 2023;13 (1) :22692. Published 2023 Dec 20. |[2]Cellini B, et al. Dual species sphingosine-1-phosphate lyase inhibitors to combine antifungal and anti-inflammatory activities in cystic fibrosis: a feasibility study. Sci Rep. 2023;13 (1) :22692. Published 2023 Dec 20.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [353770-24-8]